Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: Profectus HIV MAG pDNA vaccine, IL-12, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 13
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 8 more

Conditions: Vaccine-Preventable Diseases, COVID-19 Pandemic, Health-Related Behavior, Health Knowledge, Attitudes, Practice, Narration
Interventions: Baseline surveys, Digital Storytelling Intervention, Information Control Intervention; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Diffuse Hemispheric Glioma, H3 G34-Mutant
Interventions: Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis, Nivolumab, Placebo Administration, Poly ICLC, Resection; Biological · Procedure · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 13 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections
Interventions: ALVAC(2)120(B,MN)GNP (vCP1452), Aldesleukin; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 18 more

Conditions: Non-small Cell Lung Cancer
Interventions: Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo; Biological · Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 1,513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 49
States / cities: Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more

Conditions: Healthy Volunteers
Interventions: mRNA-1273.712, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 12 Years to 30 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 24
States / cities: Phoenix, Arizona • Huntington Park, California • La Mesa, California + 21 more

Conditions: HIV Infections
Interventions: Ritonavir, gp160 Vaccine (Immuno-AG), Stavudine, Didanosine; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1999
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy
Interventions: MEDI-534, Cohort 1, Placebo, Cohort 1, MEDI-534, Cohort 2, Placebo, Cohort 2, MEDI-534, Cohort 3, Placebo, Cohort 3, MEDI-534, Cohort 4, Placebo, Cohort 4, MEDI-534, Cohort 5, Placebo, Cohort 5; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 2 Months to 23 Months
Enrollment: 1,338 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 51
States / cities: Mobile, Alabama • Bentonville, Arkansas • Little Rock, Arkansas + 44 more

Conditions: Coronavirus Disease (COVID-19)
Interventions: V590, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Tempe, Arizona • Miami, Florida • South Miami, Florida + 4 more

Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014), PedvaxHIB, Prevnar, M-M-R II, Varivax; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 4,021 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 55
States / cities: Birmingham, Alabama • Benton, Arkansas • Jonesboro, Arkansas + 45 more

Conditions: Papillomavirus Infections
Interventions: 9vHPV Vaccine, Placebo (Saline for Injection); Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 20 Years to 45 Years · Male only
Enrollment: 6,033 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Northridge, California • Rialto, California • Simi Valley, California + 28 more

Conditions: Meningococcal Disease
Interventions: Meningococcal ABCWY, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 19 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Huntsville, Alabama • Jonesboro, Arkansas • Melbourne, Florida + 5 more

Conditions: Chickenpox
Interventions: Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investigational varicella vaccine_Lot 3, Marketed varicella vaccine_Lot 1, Marketed varicella vaccine_Lot 2, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 1,840 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 59
States / cities: Mobile, Alabama • Hot Springs, Arkansas • Sherwood, Arkansas + 50 more

Conditions: Malaria
Interventions: PfSPZ Vaccine, PfSPZ (7G8) Challenge, Sodium Chloride, 0.9%; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Refractory Generalized Myasthenia Gravis
Interventions: Eculizumab, Placebo; Biological · Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 41
States / cities: Birmingham, Alabama • Fresno, California • Los Angeles, California + 35 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: Adjuvanted RSVPreF3 vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Lexington, Kentucky • St Louis, Missouri • Omaha, Nebraska + 3 more

Conditions: Pandemic Influenza Immunization, Healthy Volunteers
Interventions: Pandemic flu H5 HA mRNA SD2 vaccine, Placebo; Biological · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: La Mesa, California • DeLand, Florida • Lakeland, Florida + 10 more

Conditions: Meningococcal Infections, Meningitis
Interventions: Menactra®, Menomune®; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 14 Years to 27 Years
Enrollment: 763 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 20
States / cities: Little Rock, Arkansas • Fountain Valley, California • Marietta, Georgia + 15 more

Conditions: HIV Infections
Interventions: SAAVI DNA-C2 vaccine, SAAVI MVA-C vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Smallpox
Interventions: IMVAMUNE; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 56 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Orlando, Florida • Iowa City, Iowa • Lexington, Kentucky + 1 more

Conditions: Respiratory Syncytial Viruses, Respiratory Tract Diseases
Interventions: RSV Vaccine, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 65 Years and older
Enrollment: 5,815 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 40
States / cities: Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 35 more

Conditions: Variola Major (Smallpox)
Interventions: Placebo, MVA-BN; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19, Vaccine Refusal
Interventions: Text Message, Motivational Interviewing, Electronic Educational Message with Tailored Questions/Prompts; Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 100 Years
Enrollment: 312 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: SARS-CoV-2 Infection, COVID-19, Maternal Immunization
Interventions: BNT162b2, Placebo; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 726 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 56
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 28 more

Search by objective public record fields.

Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

Reducing COVID-19 Vaccine Hesitancy Among Hispanic Parents

Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age

A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells

A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

First-in-Human PfSPZ-LARC2 Vaccination/CHMI

Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)

A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant

Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older

Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine

Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older

Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects

CATCH-UP Vaccines: Engaged Approaches to Testing in Community/Healthcare Settings for the Underserved (COVID-19)

To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older